Trial Profile
Non-Inferiority Trial Comparing Immunogenicity From 1-Dose of Bivalent HPV Vaccine in Girls to 3-Doses of Quadrivalent Vaccine in Women: The PRIMAVERA-ESCUDDO Trial ("Puente de Respuesta Inmunológica Para Mejorar el Acceso a Vacunas y ERrAdicar el Cancer")
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics
- Acronyms The PRIMAVERA-ESCUDDO Trial
- 25 Apr 2023 Planned End Date changed from 28 Feb 2023 to 28 Feb 2024.
- 26 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 2 Sep 2019 to 30 Sep 2019.